Alnylam Pharmaceuticals
Clinical trials sponsored by Alnylam Pharmaceuticals, explained in plain language.
-
New shot every 3 months could help hearts in rare disease
Disease control OngoingThis study tests a drug called vutrisiran in people with a rare disease that causes abnormal proteins to build up in the heart, leading to heart failure. The goal is to see if the drug can reduce deaths and heart-related hospital visits. About 655 adults took part, receiving eith…
Phase: PHASE3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 03:11 UTC
-
Heart protein disease drug tested for Long-Term safety in 700 patients
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety and effectiveness of a drug called vutrisiran in people with a heart condition caused by abnormal protein buildup (ATTR amyloidosis with cardiomyopathy). About 700 adults who were already in related studies will continue or switch to vutri…
Phase: PHASE3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated May 18, 2026 12:12 UTC
-
Real-World PH1 study tracks lumasiran safety and disease progression
Knowledge-focused OngoingThis study follows 207 people diagnosed with primary hyperoxaluria type 1 (PH1) to understand how the disease naturally progresses over time. It also tracks the long-term safety and real-world effectiveness of the drug lumasiran. The goal is to gather information that can help do…
Sponsor: Alnylam Pharmaceuticals • Aim: Knowledge-focused
Last updated May 26, 2026 03:14 UTC